These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6125830)

  • 21. [Continuous dopaminergic stimulation in Parkinson disease].
    Obeso JA; Luquin MR; Vaamonde J; Grandas F; Pastor MA; Artieda J; Martínez-Lage JM
    Neurologia; 1987; 2(5):227-34. PubMed ID: 2908545
    [No Abstract]   [Full Text] [Related]  

  • 22. Control of on/off phenomenon by continuous intravenous infusion of levodopa.
    Quinn N; Parkes JD; Marsden CD
    Neurology; 1984 Sep; 34(9):1131-6. PubMed ID: 6540399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apomorphine infusion for motor fluctuations in Parkinson's disease.
    Obeso JA; Grandas F; Vaamonde J; Rosario Luguin M; Martínez-Lage JM
    Lancet; 1987 Jun; 1(8546):1376-7. PubMed ID: 2884483
    [No Abstract]   [Full Text] [Related]  

  • 24. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations.
    Sage JI; Mark MH
    Ann Neurol; 1991 Oct; 30(4):616-7. PubMed ID: 1789688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Duodenal levodopa infusion for advanced Parkinson's disease in Finland 2006-2010].
    Pursiainen V; Pekkonen E
    Duodecim; 2012; 128(16):1707-15. PubMed ID: 23025155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.
    Kurth MC; Tetrud JW; Tanner CM; Irwin I; Stebbins GT; Goetz CG; Langston JW
    Neurology; 1993 Sep; 43(9):1698-703. PubMed ID: 8414015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D; Macías M; Llaneza M; Fuster-Sanjurjo L; Echarri-Piudo A; Belmonte S; Blanco S
    Neurologia; 2010; 25(9):536-43. PubMed ID: 21093702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of levodopa infusion on motor activation responses in Parkinson's disease.
    Feigin A; Ghilardi MF; Fukuda M; Mentis MJ; Dhawan V; Barnes A; Ghez CP; Eidelberg D
    Neurology; 2002 Jul; 59(2):220-6. PubMed ID: 12136061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa for the treatment of Parkinson's disease.
    Lewitt PA
    N Engl J Med; 2008 Dec; 359(23):2468-76. PubMed ID: 19052127
    [No Abstract]   [Full Text] [Related]  

  • 30. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.
    Quinn N; Marsden CD; Parkes JD
    Lancet; 1982 Aug; 2(8295):412-5. PubMed ID: 6124807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
    Cedarbaum JM; Silvestri M; Kutt H
    Neurology; 1990 Jun; 40(6):995-7. PubMed ID: 2345621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intravenous infusion of L-dopa: current prospective therapies].
    Peppe A; De Angelis D; Tolli VS; Rizzo PA; Scoppetta C
    Riv Neurol; 1991; 61(5):197-200. PubMed ID: 1808680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The treatment of early Parkinson's disease: levodopa rehabilitated.
    Vlaar A; Hovestadt A; van Laar T; Bloem BR
    Pract Neurol; 2011 Jun; 11(3):145-52. PubMed ID: 21551108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Ricciardi L; Bove F; Espay KJ; Lena F; Modugno N; Poon YY; Krikorian R; Espay AJ; Fasano A
    Mov Disord; 2016 Apr; 31(4):597-8. PubMed ID: 26946221
    [No Abstract]   [Full Text] [Related]  

  • 36. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
    Antonini A; Tolosa E
    Expert Rev Neurother; 2009 Jun; 9(6):859-67. PubMed ID: 19496689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. End-of-dose dystonia in Parkinson's disease.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Chase TN
    Neurology; 1993 Oct; 43(10):2130-1. PubMed ID: 8413978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levodopa delivery systems for the treatment of Parkinson's disease: an overview.
    Goole J; Amighi K
    Int J Pharm; 2009 Oct; 380(1-2):1-15. PubMed ID: 19651197
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Newly-diagnosed Parkinson's disease: a therapeutic update.
    Pleet AB
    Geriatrics; 1992 Jan; 47(1):24-9. PubMed ID: 1729144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Perioperative management of a patient with Parkinson's disease with intravenous infusion of levodopa].
    Mizuno J; Kato S; Watada M; Morita S
    Masui; 2009 Oct; 58(10):1286-9. PubMed ID: 19860235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.